Braidwell

Braidwell, founded in 2021 and located in Stamford, Connecticut, is a hedge fund that focuses on investing in public, private, and structured capital markets. The firm employs both long and short equity strategies to manage its investments. Braidwell is dedicated to serving individuals and organizations that are involved in transforming human health, reflecting its commitment to sectors that impact well-being and healthcare advancements.

Ilan Sender

Partner

20 past transactions

Caris Life Sciences

Private Equity Round in 2025
Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

Surrozen

Post in 2025
Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Perceive Pharma

Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Timberlyne Therapeutics

Series A in 2025
Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Oruka Therapeutics

Post in 2024
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

OrthoPediatrics

Post in 2024
OrthoPediatrics is a specialized medical device company focused on developing and manufacturing orthopedic implants and instruments specifically for pediatric orthopedic surgeons. The company is dedicated to enhancing the treatment of children's orthopedic conditions through the invention and distribution of innovative, anatomically appropriate implants and unique instrumentation. Its product offerings include various solutions such as PediLoc, PediPlates, Cannulated Screws, and specialized nails for pediatric use. OrthoPediatrics emphasizes the importance of creating devices that cater to the unique anatomical needs of small stature patients, ensuring both safety and efficacy in surgical procedures. The company's commitment to improving surgical experiences is exemplified by its QCR technology, which operates with minimal noise and vibration, thereby reducing patient anxiety during treatments.

Jade Biosciences

Series A in 2024
Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Day One Biopharmaceuticals

Post in 2024
Day One Biopharmaceuticals is a clinical-stage biotechnology company dedicated to developing targeted cancer therapies for patients of all ages, with a particular emphasis on pediatric patients who have historically been underserved in cancer treatment advancements. The company is committed to addressing the unique needs of children and adults facing cancer by creating therapies that are informed by the biology of childhood cancers. Day One Biopharmaceuticals aims to bring promising treatments rapidly to market, focusing on those that can benefit both younger and older patients. The company's lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target genetically defined cancers. By licensing and acquiring innovative products from research institutions and other biopharmaceutical companies, Day One Biopharmaceuticals seeks to provide effective treatment options for families confronted with the challenges of a cancer diagnosis.

Hansa Biopharma

Post in 2024
Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative therapies to address critical unmet medical needs in areas such as transplantation, autoimmune disorders, gene therapy, and oncology. Utilizing a proprietary antibody-cleaving enzyme technology platform, Hansa Biopharma targets pathogenic antibodies to enhance treatment outcomes. One of its key product candidates, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is also being explored for other organ and tissue transplantations, as well as acute autoimmune conditions. Operating primarily in Sweden, other European countries, and the United States, Hansa Biopharma generates the majority of its revenue from product sales.

Cullinan Therapeutics

Post in 2024
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Lexicon Pharmaceuticals

Post in 2024
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

Lexeo Therapeutics

Post in 2024
Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

iRhythm Technologies

Post in 2024
iRhythm Technologies, Inc. is a digital healthcare company based in San Francisco, California, specializing in ambulatory electrocardiogram (ECG) monitoring for patients at risk of arrhythmias. The company offers the Zio service, an advanced cardiac monitoring solution that integrates a wire-free, patch-based biosensor with a cloud-based analytics platform, enabling physicians to monitor patients effectively and diagnose arrhythmias. The Zio Patch, its flagship product, is designed for up to 14 days of monitoring and is notable for being small, lightweight, and unobtrusive. iRhythm's technology combines wearable biosensing with machine learning to transform vast amounts of cardiac data into actionable clinical insights, ultimately aiming to improve patient health outcomes and reduce healthcare costs. Founded in 2006, iRhythm continues to innovate in the field of cardiac care and has partnered with Verily Life Sciences to develop next-generation products for atrial fibrillation detection and monitoring.

Nevro

Post in 2023
Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Krystal Biotech

Post in 2023
Krystal Biotech, Inc. is a biopharmaceutical company based in Pittsburgh, Pennsylvania, specializing in gene therapy for patients with rare skin diseases. Founded in 2015, the company develops innovative treatments using its proprietary STAR-D gene therapy platform, which targets dermatological conditions caused by genetic mutations. Its lead candidate, beremagene geperpavec (B-VEC), is in clinical development for dystrophic epidermolysis bullosa, having completed Phase I/II studies. Krystal Biotech is also advancing other product candidates, including KB105, which is in Phase I/II trials for autosomal recessive congenital ichthyosis, and KB301 and KB104, which are in preclinical stages for aesthetic skin conditions and Netherton Syndrome, respectively. Additionally, the company is exploring treatments for chronic skin diseases through its discovery-stage candidate KB5xx. Krystal Biotech aims to enhance the quality of life for patients suffering from debilitating skin disorders with its gene therapy solutions.

Caris Life Sciences

Debt Financing in 2023
Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

Perceive Biotherapeutics

Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages advanced protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By employing multiple therapeutic modalities, Perceive Biotherapeutics aims to provide medical professionals with effective solutions for preventing vision loss and enhancing patient outcomes in the field of ophthalmology.

Compass Therapeutics

Post in 2022
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Allakos

Post in 2022
Allakos Inc. is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Redwood City, California. The company focuses on developing antibody-based therapeutics aimed at treating diseases associated with dysregulation of the T-helper type 2 immune response, which plays a crucial role in various allergic and inflammatory conditions. Its lead product, antolimab (AK002), is being investigated for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets the Siglec-6 receptor on mast cells, designed to activate the receptor's inhibitory function and reduce mast cell activation. Through these innovative therapies, Allakos aims to address the underlying mechanisms of diseases characterized by excessive inflammatory responses.

DBV Technologies

Post in 2022
DBV Technologies S.A. is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, focused on developing innovative treatments for food allergies through epicutaneous immunotherapy. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. Additionally, DBV Technologies is advancing Viaskin Milk, which is in Phase I/II trials for cow’s milk protein allergy and related conditions, and Viaskin Egg, currently in pre-clinical development for hen’s egg allergy. The company is also exploring a booster vaccine for Bordetella pertussis and has ongoing research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. Notably, DBV Technologies collaborates with Nestlé Health Science to develop MAG1C, an atopy patch test aimed at diagnosing non-IgE mediated cow’s milk protein allergy in infants and toddlers. Founded by pediatricians and entrepreneurs in 2002, DBV Technologies aims to revolutionize the field of immunotherapy by safely activating the immune system through its proprietary Viaskin technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.